Patent classifications
A61K39/02
BURKHOLDERIA PSEUDOMALLEI COMPLEX OUTER MEMBRANE VESICLES AS ADJUVANTS
Outer membrane vesicles from bacteria of the Burkholderia pseudomallei complex can be used as adjuvants in compositions and methods to potentiate the immune response to immunogens.
BURKHOLDERIA PSEUDOMALLEI COMPLEX OUTER MEMBRANE VESICLES AS ADJUVANTS
Outer membrane vesicles from bacteria of the Burkholderia pseudomallei complex can be used as adjuvants in compositions and methods to potentiate the immune response to immunogens.
A VACCINE TO PROTECT AGAINST MYCOPLASMA HYOPNEUMONIAE
A vaccine comprising nanoparticles in association with a Mycoplasma hyopneumoniae bacterin, wherein the nanoparticles comprise a cationic polysaccharide and an anionic phospholipid.
A VACCINE TO PROTECT AGAINST MYCOPLASMA HYOPNEUMONIAE
A vaccine comprising nanoparticles in association with a Mycoplasma hyopneumoniae bacterin, wherein the nanoparticles comprise a cationic polysaccharide and an anionic phospholipid.
IMMUNOGENIC GEL COMPOSITIONS
An immunogenic gel compositions for oral administration and methods of immunizing an animal the methods including administering to the animal a therapeutically effective amount of an immunogenic gel composition comprising an antigen of an animal pathogen and a gel composition for oral administration.
IMMUNOGENIC GEL COMPOSITIONS
An immunogenic gel compositions for oral administration and methods of immunizing an animal the methods including administering to the animal a therapeutically effective amount of an immunogenic gel composition comprising an antigen of an animal pathogen and a gel composition for oral administration.
Methods for treating plague
Provided herein are methods for using compositions that include a fusion protein having a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. In one embodiment the composition is used to confer immunity to plague, such as pneumonic plague, caused by Yersinia pestis. In one embodiment, the composition is administered to a mucosal surface, such as by an intranasal route. In one embodiment, the administration to a mucosal surface includes a vector that has a polynucleotide encoding a fusion protein, where the fusion protein includes a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. The administration is followed by a second administration by a different route, such as an intramuscular route. The second administration includes a fusion protein having the same three domains, and in one embodiment the fusion protein is the same one administered to a mucosal surface.
USE OF A HYPERIMMUNE EGG PRODUCT TO PREVENT AND TREAT DYSBIOSIS
Methods for treating and preventing dysbiosis in a subject suffering from or susceptible to gastrointestinal disorders are described. The methods comprises administering a hyperimmunized egg product to the subject, wherein the egg product is obtained from a hyperimmunized avian, optionally in combination with an additional compound such as a probiotic and/or nutrient source.
USE OF A HYPERIMMUNE EGG PRODUCT TO PREVENT AND TREAT DYSBIOSIS
Methods for treating and preventing dysbiosis in a subject suffering from or susceptible to gastrointestinal disorders are described. The methods comprises administering a hyperimmunized egg product to the subject, wherein the egg product is obtained from a hyperimmunized avian, optionally in combination with an additional compound such as a probiotic and/or nutrient source.
Attenuated live vaccine against mycoplasmal pneumonia of swine (MPS) and use thereof
Disclosed are an attenuated live vaccine against mycoplasmal pneumonia of swine (MPS) and use thereof. In the present invention, pathological lung tissues of swine having typical Mycoplasma hyopneumoniae (Mhp) infection and no obvious other pathogenic infections are screened, and subcultured 100 generations in lungs of newborn rabbits; then, Mhp strains are isolated and serially subcultured in a medium; and the Mhp strain AN306 is obtained by screening a plurality of strains, which is deposited with an accession number: CCTCC NO. M2012431. Also disclosed is a live vaccine formulation against MPS prepared on the basis of the attenuated strain and comprising live attenuated strain, a pharmaceutically acceptable carrier or excipient, and optionally an adjuvant and immunogens of other pathogens.